RET and medullary thyroid gland carcinoma: The population data presented here (unbiased in its ascertainment by phenotype) reflect that the distribution of modifying factors across the general population is such that only ∼4% of individuals have a sufficient dose of modifiers, such that they will develop MTC when carrying RET p.Val804Met.